Voclosporin

Base Information

• Chemical Name: Voclosporin
• CAS No.: 515814-01-4
• Deprecated CAS: 368455-04-3
• Molecular Formula: C30H57N3O5
• Molecular Weight: 539.79068
• European Community (EC) Number: 881-570-5
• UNII: 2PN063X6B1
• DSSTox Substance ID: DTXSID401030488
• Nikkaji Number: J3.038.009F
• Wikipedia: Voclosporin
• Wikidata: Q7939256
• NCI Thesaurus Code: C152902
• RXCUI: 2475166
• Metabolomics Workbench ID: 152807
• Mol file: 515814-01-4.mol

Synonyms:ISA 247;ISA(TX)247;ISA-247;ISATX247;lupkynis;voclosporin

Chemical Property of Voclosporin

Chemical Property:

• Boiling Point: 1303.8±65.0 °C(Predicted)
• PKA: 13.32±0.70(Predicted)
• PSA: 278.80000
• Density: 1.016±0.06 g/cm3(Predicted)
• LogP: 4.31560
• XLogP3: 7.9
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 12
• Rotatable Bond Count: 16
• Exact Mass: 1213.84136802
• Heavy Atom Count: 86
• Complexity: 2380

Purity/Quality:

98% min ^*data from raw suppliers

Voclosporin 99.20% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Immunosuppressive Agents
• Canonical SMILES: CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
• Isomeric SMILES: CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
• Recent ClinicalTrials: Long-Term Voclosporin Treatment in Adolescent Subjects With Lupus Nephritis
• Recent EU Clinical Trials: A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis
• Recent NIPH Clinical Trials: AURORA 2: Aurinia Renal Response in Lupus Nephritis with Orelvo (voclosporin)
• Uses: Voclosporin is a new agent for the treatment of noninfectious uveitis. Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss . Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. A new agent for the treatment of noninfectious uveitis. Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. Immunosuppressant.